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Introduction: Visceral ischemia nd reperfusion associated with thoracoabdominal aortic 
aneurysm (TAAA) repair results in lung injury, which appears to be mediated in part by 
proinflammatory c tokines. The purpose of this study was to determine the effect of 
exogenous administration of the antiinflammatory c tokine, recombinant human IL-10 
(rhIL-10), on proinflammatory c tokine production (IL-6 and TNFot) and pulmonary 
neutrophil nfiltration after acute visceral ischemia-reperfusion. 
Methods: Two hours before 25 minutes of supraceliac aortic occlusion, 80 C57BL/6 mice 
(20 to 22 g) received an intraperitoneal injection ofrhIL-10 (0.2 ~g [n = 20], 2 ~g [n = 
20], 5 ~g [n = 25], or 20 ~g [n = 15]), and 16 mice received murine anti-IL-10 IgM 
200 I~g. Twenty-five additional mice underwent visceral ischemia-reperfusion without 
treatment (controls), and 16 mice underwent laparotomy without aortic occlusion 
(sham). 
Results: Pretreatment with exogenous rhIL-10 resulted in significant reductions in lung 
neutrophil nfiltration with 0.2 ~g, 2 I~g, and 5 ~g per mouse ofrhIL-10 compared with 
lung neutrophil levels in control mice that underwent acute visceral ischemia-reperfusion 
alone (p < 0.05). In addition, serum TNFet was detected in 50% of control mice and in 
75% of mice that received murine anti-IL-10, but in none of the mice that received 
rhIL-10 (2 I~g per mouse) or the mice that underwent sham operative procedures (p < 
0.05 by X 2 analysis). 
Conclusion: Exogenous IL-10 limits pulmonary neutrophil recruitment and the appear- 
ance of TNFet in this model of visceral ischemia-reperfusion njm T. Thus the use of 
exogenous IL-10 may offer a novel therapeutic approach to decrease the complications 
that are associated with TAAA repair. (J Vasc Sure 1997;26:113-8.) 
Visceral ischemia-reperfusion produces local in- 
jury both to the visceral organs that were made isch- 
emic and to distant organs, such as the lungs, that 
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were not made ischemic. Animal studies have dem- 
onstrated that the pulmonary injury after visceral 
ischemia-reperfusion s in part a result of  the produc- 
tion and release of a variety of humoral factors. These 
humoral factors include proinflammatory c tokines, 
activated complement, and lipid mediators, includ- 
ing platelet activating factor, prostanoids, leukotri- 
enes, and lipoxinsY s Two proinflammatory c tokines, 
tumor necrosis factor ~ (TNFc~) and interleukin (IL)-1, 
have been implicated as early initiators of this'response 
to visceral ischemia-reperfusion njury. For example, 
the pathologic hanges associated with visceral isch- 
emia-reperfusion can be blocked by pretreatment 
with inhibitors of these proinflammatory cyto- 
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kines. 8,9 The clinical importance of this inflammatory 
response after acute visceral ischemia nd reperfusion 
can be seen after thoracoabdominal aortic aneurysm 
(TAAA) repair, for which the incidence of pulmonary 
injury (20% to 47%), altered renal function (20% to 
30%), hepatic dysfunction (5% to 15%), multisystem 
organ dysfimction (5%), and death (5%) are directly 
related to visceral ischemic time and a proinflammatory 
response. 10-13 
IL-10 inhibits proinflammatory cytokine produc- 
tion by activated monocytes/macrophages nd pre- 
vents TNF~ production in acute inflammatory 
states. 14-17 IL-10 is currently in use in the treatment 
of patients who have inflammatory bowel disease and 
rheumatoid arthritis, and potentially could have ap- 
plications in the treatment of patients who undergo 
TAAA repair. This study investigates this question in 
a murine model of acute visceral ischemia similar to 
that that occurs during TAAA repair and demon- 
strates that initial lung neutrophil infiltration and 
TNFo~ production can be inhibited by pretreating 
mice with recombinant human IL-10 (rhIL-10). 
MATERIALS AND METHODS 
Animal preparation 
Female C57BL/6 mice (20 to 22 g; Charles 
River Breeding Laboratories, Wilmington, Mass.) 
were anesthetized with 35 mg/kg body weight of 
intraperitoneal sodium pentobarbital. A laparotomy 
was then performed and the bowel exteriorized. The 
supraceliac aorta, the celiac axis, and the superior 
mesenteric artery were identified, and a microvascu- 
lar clamp (10 mm) was placed across the supraceliac 
aorta. Cessation of blood flow to the bowel and 
visceral organs was confirmed by lack of pulsation in 
the mesenteric arterial arcades, loss of liver volume, 
blanching of the liver, and darkening of the spleen. 
Each mouse was given 50 ml/kg of physiologic sa- 
line solution by intraperitoneal injection for crystal- 
loid support, and the abdominal wall was reapproxi- 
mated to avoid evaporative fluid loss during the 
period of visceral ischemia. 
After 25 minutes of acute visceral ischemia, the 
abdomen was reopened and the supraceliac ross- 
clamp removed with return ofpulsatile blood flow to 
the abdominal viscera. Each mouse was then given an 
additional 50 ml/kg of physiologic saline solution by 
intraperitoneal injection, and the abdominal incision 
was closed again. Mice were killed after 2 hours of 
reperfusion. Two hours ofreperfusion was chosen as 
the endpoint for these studies on the basis of previ- 
ous work from our laboratory that demonstrated that 
maximal murine serum IL-IO levels and peak lung 
myeloperoxidase (MPO) levels occur 2 hours after 
visceral ischemia-reperfusion in this model (unpub- 
lished data and WelbornS). In those studies, the 
concentrations of proinflammatory c tokines and 
lung neutrophil infiltration were evaluated over a 
I2-hour period after visceral ischemia-reperfusion in- 
jury, and peak responses were seen at 2 hours. Blood 
samples were then obtained via cardiac puncture and 
serum stored at -70°C for later measurement of
murine IL-6, hIL-10, and murine TNFc~ levels. 
Lungs were also harvested, rinsed in normal saline, 
flash-frozen, and subsequently stored at -70 ° C for 
later assessment of neutrophil nfiltration. Mice that 
underwent the identical procedures without place- 
ment of the supraceliac lamp were used as sham 
operative controls. 
Experimental groups 
Two hours before aortic cross-damping, 80mice 
received an intraperitoneal injection of recombinant 
human IL-IO (0.2 ~g (n = 20), 2 ~g (n = 20), 5 ~g 
(n = 25), or 20 Ixg (n = 15)/mouse), whereas 16 
mice received intraperitoneal purified murine anti- 
IL-10 immunoglobulin M (IgM; 200 }xg/mouse 
[10 mg/kg]). Twenty-five additional mice under- 
went visceral ischemia-reperfusion without reatment 
with rhlL-10 or anti-IL-10 (controls), and 16 mice 
underwent sham procedures as previously described 
(sham). 
All protocols were approved by the Institutional 
Animal Care and Use Committee and the laboratory 
adheres to the Guiding Principles of Laboratory An- 
imal Care as promulgated by the American Physio- 
logic Sodety. 
Determination of pulmonary injury 
MPO assay. Pulmonary neutrophil sequestra- 
tion was quantitated by measuring tissue MPO lev- 
els. Thawed lung samples were weighed and homog- 
enized in 0.01 mol/L IG-I2PO4 at a ratio of 1:15 
weight for volume. After homogenization the result- 
ant supernatant was discarded, and thc pcllct was 
resuspcnded in cetyltrimethylammonium bromide 
buffer at a ratio of 1:5 weight for volume. This 
solution was then incubated at 60 ° C for 2 hours, 
followed by sonication for 1 minute. The resultant 
supernatant was collected for mcasurcmcnt of MPO 
concentrations, which were determined using the 
H202-dependent oxidation of 3,3'5,5'-tetramethyl- 
benzine, which generates a colorimetric reaction. 
Spectrophotometric absorbance was read at 650 nm 
and compared with a linear standard curve with a 
sensitivity of 0.0625 EU. 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 1 Hess et al. 115 
Cytokine determinations 
Murine IL-6 and human IL-10. Serum cyto- 
kine levels were determined as previously de- 
scribed) s Briefly, murine serum IL-6 concentrations 
were determined by sandwich enzyme-linked immu- 
nosorbent assay (ELISA; Endogen, Inc., Boston, 
Mass.), with a sensitivity of 63 pg/ml.  Human IL-10 
serum levels were determined using an ELISA that 
does not cross-react with murine IL-10, with a sen- 
sitivity of 3I pg/ml.  Serum hIL-10 levels were mea- 
sured in mice that received 0.2 txg, 2 Ixg, and 5 txg 
doses of  rh lL - I0  to assess absorption from the 
peritoneal cavity and appearance in the intravascu- 
lar compartment. 
TNFot. Bioactive TNF was measured using the 
WEHI  164 clone 13 murine fibrosarcoma cell line. ~9 
The cells were cultured in 96 well plates and were 
then exposed either to diluted serum samples or to 
increasing concentrations of recombinant human 
TNF~. The cell viability was determined by the 
reduction Of MTT (3-[4,5-dimethylthiazol-2-yl]- 
2,5-diphenyltetrazolium bromide) and quanti- 
tated at 570 nm. A standard curve was generated 
with human TNF% and the sensitivity of the assay 
was 5 pg/ml .  
Because of the small volumes of blood obtained 
from these mice at 2 hours (generally less than 500 
txL) and the volumes of plasma sample required for 
each ELISA (100 Ix/assay), itwas not always possible 
to measure ach and every cytokine on every sample. 
Therefore, the number of subjects for each group is 
often less than the numbers of mice studied. 
Statistical analysis 
Statistical analysis was carried out using one-way 
analysis of  variance (ANOVA) for comparison 
among treatment groups (SigmaStat, Jandel Scien- 
tific, San Rafael, CA). In cases in which normality 
was not obtained (plasma TNF concentrations), a 
Kruskal-Wallis one-way ANOVA on ranks was per- 
formed. A post-hoc omparison among the different 
groups was undertaken with either a Newman-Keuls 
multiple range test or Dunn's method. Differences in 
the frequency of detecting TNF bioactivity were de- 
termined using ×2 analysis. Statistical significance was 
considered achieved if the p value was less than 0.05. 
All values are presented as the mean _+ standard error 
of the mean. 
RESULTS 
Lung MPO 
Ischemia-reperfusion injury produced a signifi- 
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Fig. 1. Lung MPO levels in experimental groups. After 2 
hours of reperfusion, lung MPO levels in mice that re- 
ceived 0.2 Ixg, 2 ixg, or 5 ixg ofrhlL-10 were significantly 
reduced compared with control mice or those pretreated 
with 200 /xg murine anti-IL-10. Values represent mean 
and standard error of mean of between 6 and 25 observa- 
tions per group. Samples were analyzed by ANOVA, and 
post hoc comparisons were performed using Dunn's 
method. *p < 0.05 versus controls. 
sham procedure (Fig. 1). In mice with ischemia- 
reperfusion i jury, MPO levels were only suppressed 
in mice that wcrc pretreated with 0.2 v~g, 2 ~g, and 5 
txg/mouse of rhIL-10 (Fig. 1). MPO values from 
micc trcatcd with these doses of rhIL-10 were also 
equivalent to levels from sham treated mice. In con- 
trast, mean MPO levels from micc treated with 20 
~xg/mouse of rhIL-10 were equivalent o valucs 
from ischemia-reperfusion injury control mice. Mean 
MPO levels in mice treated with anti-IL-10 were also 
not different from control mice. 
IL-6 
Murine IL-6 was detectable in the serum of all 
mice studied, including those subjected to sham op- 
erative procedures. However, ischemia-reperfusion 
injury significantly increased the plasma IL-6 re- 
sponse at the 2 hour period (Fig. 2). Administration 
of IL-10 tended to increase the plasma IL-6 response 
in all of the groups, although the difference between 
mean serum IL-6 levels in mice that received rhlL-10 
and in the control mice was significant only at the 
highest dose ofrhIL-10 (Fig. 2). Mean IL-6 levels in 
mice treated with anti-IL-10 (40,698 -+ 11,210) 
were also significantly higher than ischemia-reperfu- 
sion injury controls. 
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Fig. 2. Plasma IL-6 levels from mice after supraceliac 
aortic cross-clamping. The concentrations of IL-6 signifi- 
cantly increased in mice treated with 5 ~g recombinant 
human IL-10 or monoclonal antibody to IL-10. Values 
represent mean and standard error of mean of between 8
and 21 observations per group. Samples were analyzed by 
ANOVA, and post hoc comparisons were performed using 
Dunn's method. *p < 0.05 versus controls. 
Human IL-IO 
Recombinant human IL-10 was detected in thc 
serum of all of the mice in which recombinant hu- 
man IL-10 was administered, whereas no human 
IL-10 was detected in control or sham mice (Fig. 3). 
The mean circulating rhIL-10 level was significantly 
higher in mice treated with 5 Ixg/mouse ofrhIL-10 
(5060 -+ 1151 pg/ml)  than in mice that received 
doses of 0.2 Ixg and 2 b~g/mouse ofrhIL-10 (237 -+ 
98 and 773 +_ 63 pg/ml,  respectively; Fig. 3). 
TNFot 
TNF~ was detected in the serum of 50% (4 of  8) 
of the control mice, none (0 of 8) of  the mice that 
received 2 ~g ofrhIL-10, none (0 of 8) of the mice 
that underwent sham operative procedures, and 75% 
(6 of  8) of the mice that received anti-IL-10 (p < 
0.05 by X 2 analysis). The mice that were pretreated 
with anti-IL-10 had mean circulating TNFe~ levels 
(17 + 4 pg/ml)  that were statistically higher (by 
Kruskal-Wallis ANOVA on ranks, p < 0.05) than 
TNF~ levels from control mice (0 + 0 pg/ml)  or 
from mice that underwent acute visceral ischemia- 
reperfusion alone (10 -+ 4 pg/ml).  
DISCUSSION 
Morbidity and mortality rates after the repair of 
TAAAs are significantly higher than after the repair 
ofinfrarenal abdominal aortic aneurysms. 1°-1s,2° Vis- 
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Fig. 3. Plasma recombinant human IL-10 levels from 
mice after intraperitoneal injection. After 2 hours of 
reperfusion, rhlL-10 was detectable inall groups of mice 
that received intraperitoneal injections. Significantly 
higher peak circulating serum rhlL-10 values were ob- 
served in mice that were pretreated with 5 ixg rhIL-10. 
Values represent mean and standard error of mean of 
between 8 and 16 observations per group. Samples were 
analyzed by ANOVA, and post hoc comparisons were 
performed using Dunn's method. *p < 0.05 versus 
controls. 
have recently been shown by Harward et al. 18 to 
produce a significant proinflammatory c toldne re- 
sponse, and circulating TNF levels appear to be an 
important determinant of the risk of organ dysfunc- 
tion after TAAA repair. As opposed to many of the 
other risk factors for complications after TAAA re- 
pair, the proinflammatory c tokine response that is 
generated by visceral ischemia-reperfusion can be 
modulated by anticytokine therapy, which might re- 
duce morbidity and mortality rates. 
This study demonstrates that, in mice, reperfu- 
sion of the visceral organs after a period of suprace- 
liac aortic occlusion similar to that that occurs during 
TAAA repair in human beings produces a distant 
lung injury that can be attenuated by pretreatrnent 
with rhIL-10. In addition, production of TNF~x after 
acute visceral ischemia-reperfusion was suppressed by 
doses of exogenously administered rhIL-10 that 
maximally suppressed lung neutrophil infiltration. 
Conversely, inhibition of endogenous IL-10 activity 
with anti-IL-10 antibodies exacerbated the IL-6 re- 
sponse after acute visceral ischemia-reperfusion, but 
did not worsen the degree of lung neutrophil nfiltra- 
tion. This latter finding suggests that an endogenous 
IL-10 response may attenuate plasma IL-6, but has 
little direct effect on the early neutrophil nfiltration. 
IL-10 is an immunosuppressive and antiinflam- 
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matory cytokine that is produced by T-cells, natural 
killer cells, and macrophage/monocyte ell lines. 2L22 
Among the many important regulatory properties 
attributed to IL-10 is the inhibition ofproinflamma- 
tory cytokine production in models of acute inflam- 
mation. 23 IL-10 has been shown to suppress the 
production of TNFa, IL-l% IL-lf3, and IL-8 by 
human monocytes and mouse peritoneal macro- 
phages 14-17 and to limit the mortality rate in a murine 
model of endotoxemic shock. 24,2s 
The data presented here indicate that in a murine 
model the most beneficial effects of exogenously ad- 
ministered rhIL-10 were obtained at the lower doses 
(i.e., 0.2 txg, 2 b~g, and 5 Ixg/mouse), whereas the 
highest dose was ineffective at preventing neutrophil 
infiltration. At the present time, a ready explanation 
for this observation is lacking. However, IL-10 being 
a pluripotent cytokinc with immunomodulatory 
properties in addition to its antiinflammatory actions 
may well have had an impact on pathways distinct 
from proinflammatory cytokines like TNFc~. Clearly, 
Moore and others have implicated lipid mediators 
(platelet-activating factor [PAF], leukotrienes, pros- 
tanoids) in the neutrophil priming and activation 
that accompanies i chemia-reperfusion injury, 3°26 
and the interactions between IL-10, IL-6, prostan- 
oids, and PAF are still unresolved. For example, BiN 
and colleagues 27have implicated a role for IL-6 in 
potentiating PAF-mediated neutrophil priming, 27 
and in the present studies, the highest dose oflL-10 
significantly increased the plasma IL-6 response. 
The cause of the increase in serum IL-6 levels 
seen with increasing doses ofrhlL-10 in the current 
study remains unclear. In in vitro studies designed to 
examine the effect of IL-10 on vascular endothelium, 
Sironi et al. 28 demonstrated that murine IL-10 in- 
duced low levels of IL-6 production and amplified 
induction of IL-6 by lipopolysaccharide n a murine 
endothelioma cell line. 28 Therefore, exogenously ad- 
ministered rhlL-10, as well as endogenous murine 
IL-10 produced in response to visceral ischemia- 
reperfusion, may stimulate ndothelial or other cell 
lines to produce IL-6 in vivo, similar to the in vitro 
results of Sironi et al. 
In a recent clinical trial, Huhn et al.29 found that 
patients who received 0.1 to 100 Ixg/kg intravenous 
rhlL-10 experienced a verse ffects (mild flulike syn- 
drome) only at the highest dose and that the half life 
of rML-10 after intravenous injection was approxi- 
mately 4 hours. Furthermore, the lowest doses of 
IL-10 that were not accompanied by any adverse 
effects were effective at reducing ex vivo proinflam- 
matory responses. These'observations, along with 
the data from the present study, suggest that pre- 
treating patients with low doses of rhIL-10 will be 
well tolerated and may limit the initial pulmonary 
injury and the initial proinflammatory response that 
are associated with visceral ischemia-reperfusion, and
thus possibly reduce pulmonary or other distal organ 
injury after procedures such as TAAA repair. 
The systemic proinflammatory cytokine response 
is likely only one of the factors involved in pulmonary 
injury after acute visceral ischemia-reperfusion. 
Clearly, other humoral factors are involved in this 
process, including C3a, C5a, PAF, leukotrienes, and 
other prostanoid products. In reality, proinflamma- 
tory cytokines and these other humoral factors are 
tightly interrelated. Because of this interrelation, it is 
not clear whcthcr suppression of the cytokine re- 
sponse alone after acute visceral ischemia-reperfusion 
will result in a clinically significant reduction in pul- 
monary or other distant organ dysfunction at later 
time points. The response to visceral ischemia-reper- 
fusion in the current study was only investigated after 
2 hours of reperfusion, and exogenous rhIL-10 may 
only delay rather than limit pulmonary dysfunction 
associated with acute visceral ischemia. Nevertheless, 
even the initial reduction in the pulmonary neutro- 
phil sequestration seen in this study in mice treated 
with exogenous rhlL10 may reduce both the risk of 
the initial pulmonary injury and later pulmonary in- 
jury because of a sccond insult such as bacterial 
contamination. 
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